NVS - Genmab ups guidance on $30M Novartis payment for Arzerra royalties August, 20 2020 04:25 PM Novartis AG Genmab A/S (NASDAQ:GMAB) will receive a $30M payment from licensee Novartis (NYSE:NVS) to account for lost royalties from blood cancer med Arzerra (ofatumumab).More news on: Genmab A/S, Novartis AG, Healthcare stocks news, Read more ...